加速康复外科中多拉司琼预防髋关节置换患者术后恶心呕吐的效果

Abstract
Figure/Table
References (20)
Related Citation (15)

Download: PDF (0 KB) HTML (35 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect of Dolasetron in enhanced recovery after surgery (ERAS) in preventing postoperative nausea and vomiting in patients with hip replacement.Methods From January to December 2018,60 patients in the Second People′s Hospital of Shantou who needed artificial total hip replacement were selected as the research objects and they were divided into the study group (n=30) and the control group (n=30) by the random number table method.Both of the two groups were treated with unilateral artificial total hip replacement and had perioperative ERAS intervention,and the patients in the study group received intravenous drip of 12.5 mg Dolasetron Mesylate half an hour before skin incision to prevent postoperative nausea and vomiting.The postoperative nausea and vomiting rate and total incidence rate of complications between the two groups were compared.The visual analogue scale (VAS) was used to evaluate the pain symptoms before and after operation of the two groups,and the Harris hip joint function score was used to evaluate the recovery of hip joint function in the two groups at 3 months after the operation.Results The nausea and vomiting rate,total incidence rate of complications,and the VAS scores at 1 and 3 months after operation in the study group were lower than those in the control group,and the Harris hip joint function score at 3 months after operation in the study group was higher that in the control group,with statistically significant differences (P＜0.05).The VAS scores of the two groups at 1 and 3 months after operation were lower than those before operation in the same group,with statistically significant differences (P＜0.05).Conclusion Dolasetron has a good effect in the intervention of ERAS,which can effectively prevent nausea and vomiting and promote the recovery of joint function in patients with hip replacement,and is worthy of promotion and application.

Key words： Dolasetron Prevention Hip replacement Nausea Vomiting Enhanced recovery after surgery

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZENG Geng-hui
	TU Xin-xiang
	HU Qin-qing

Cite this article:

ZENG Geng-hui,TU Xin-xiang,HU Qin-qing. Effect of Dolasetron in enhanced recovery after surgery in preventing postoperative nausea and vomiting in patients with hip replacement[J]. 中国当代医药, 2021, 28(1): 163-165转169.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I1/163

[1]	米尔阿里木·木尔提扎，赵巍，瓦热斯江·尼牙孜，等.直接前侧入路与前外侧入路全髋关节置换的差异：基于置换后早期患者主观感受的比较[J].中国组织工程研究，2020，24（9）：1318-1323.
[2]	闫堃，程玮，曹罡，等.帕洛诺司琼预防腹腔镜低位保肛直肠癌根治结合缓释型氟尿嘧啶植入术后恶心呕吐的作用及安全性[J].中国新药与临床杂志，2019，38（4）：219-222.
[3]	李卡，刘雨薇，冯金华，等.加速康复外科模式在全髋关节置换术围术期管理中的临床研究[J].四川大学学报（医学版），2019，50（4）：604-608.
[4]	曾耿晖，胡钦擎，周吾钊.甲磺酸多拉司琼在预防小儿患者术后恶心呕吐的疗效观察[J].江西医药，2019，54（10）：1283-1284.
[5]	陈敏，郑亚婷，唐强.加速康复外科护理对髋关节置换术后并发症及功能的影响[J].全科护理，2017，15（33）：4138-4139.
[6]	王民，高博，马越，等.髂筋膜间隙阻滞对老年全髋关节置换术后疼痛的影响[J].中国现代医学杂志，2017，27（5）：94-99.
[7]	覃勇志，周宗科.人工全髋关节置换术治疗化脓性髋关节炎后遗骨关节病的研究进展[J].中国修复重建外科杂志，2020，34（1）：139-144.
[8]	朱江龙，陈跃平，董盼锋，等.老年骨质疏松症患者髋关节置换术后预后及相关因素分析[J].中国骨质疏松杂志，2019，25（8）：1073-1077.
[9]	王声祥，任艳平，李楠，等.阿哌沙班、利伐沙班、达比加群酯、依诺肝素预防髋膝关节置换术后静脉血栓形成的成本-效果分析[J].中国医院药学杂志，2020，40（2）：208-212.
[10]	蒋巧玲，沈锦涛，郭会利.股骨头坏死愈胶囊联合多孔钽棒治疗早期股骨头坏死临床观察[J].风湿病与关节炎，2017，6（10）：22-26.
[11]	李炯.甲磺酸多拉司琼与盐酸格拉司琼预防术后恶心呕吐的临床对照研究[J].中国继续医学教育，2016，8（17）：69-70.
[12]	覃韬，黎阳，谢显龙，等.全身麻醉患者术后恶心呕吐相关因素分析[J].医药导报，2019，38（11）：1442-1445.
[13]	佟冰渡，高娜，马玉芬，等.髋膝关节置换患者术后恶心呕吐发生现状及影响因素研究[J].护理学杂志，2018，33（9）：34-37.
[14]	周芷筠，王琳，钟海利，等.药学干预对临床帕洛诺司琼止吐预防性使用的影响[J].中国医院药学杂志，2018，38（4）：431-435.
[15]	冯素琴，林友媚，宫庆娟，等.经皮穴位电刺激防治舒芬太尼所致术后恶心呕吐的临床研究[J].中国疼痛医学杂志，2018，24（5）：364-366，372.
[16]	Morrow GR，Schwartzberg L，Barbour SY，et al.Palonosetron versus older 5-HT3 receptor antagonists for nausea prevention in patients receiving chemotherapy：a multistudy analysis[J].J Community Support Oncol，2014，12（7）：250-258.
[17]	陈颖，殷佳晗，丁雯，等.术中液体治疗对甲状腺手术患者术后恶心呕吐的影响[J].上海医学，2019，42（2）：81-83.
[18]	Faria C，Li X，Nagl N，et al.Outcomes Associated with 5-HT3-RA Therapy Selection in Patients with Chemotherapy-Induced Nausea and Vomiting：A Retrospective Claims Analysis[J].Am Health Drug Benefits，2014，7（1）：50-58.
[19]	陶婷，齐龙华.多拉司琼对胃肠手术后患者恶心呕吐的预防效果观察[J].医学理论与实践，2020，33（1）：89-90.
[20]	王静，吴开花，李立波，等.多拉司琼对腹腔镜胆囊切除术患者术后恶心呕吐的预防和疗效观察[J].临床检验杂志（电子版），2017，6（4）：772-773.